MX2022013984A - Inhibidores de cinasa 7 relacionada con el gen nunca en mitosis a (nek7). - Google Patents

Inhibidores de cinasa 7 relacionada con el gen nunca en mitosis a (nek7).

Info

Publication number
MX2022013984A
MX2022013984A MX2022013984A MX2022013984A MX2022013984A MX 2022013984 A MX2022013984 A MX 2022013984A MX 2022013984 A MX2022013984 A MX 2022013984A MX 2022013984 A MX2022013984 A MX 2022013984A MX 2022013984 A MX2022013984 A MX 2022013984A
Authority
MX
Mexico
Prior art keywords
sup
nek7
inhibitors
compounds
kinase
Prior art date
Application number
MX2022013984A
Other languages
English (en)
Inventor
David James Bearss
Iii John Sai Keong Kauwe
Alexis Henri Abel Mollard
Original Assignee
Halia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Halia Therapeutics Inc filed Critical Halia Therapeutics Inc
Publication of MX2022013984A publication Critical patent/MX2022013984A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proporcionan compuestos que tienen actividad como inhibidores de NEK7. Los compuestos tienen la Estructura (I): (ver Fórmula) (I) o una sal, estereoisómero o profármaco farmacéuticamente aceptable de los mismos, caracterizado porque A, X, Y, R1, R2, R3, R 4y R5 son como se definen aquí. También se proporcionan métodos asociados con la preparación y el uso de los compuestos, composiciones farmacéuticas que comprenden los compuestos y métodos para modular la actividad del inflamasoma NLRP3.
MX2022013984A 2020-05-08 2021-05-07 Inhibidores de cinasa 7 relacionada con el gen nunca en mitosis a (nek7). MX2022013984A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063022159P 2020-05-08 2020-05-08
US202163170761P 2021-04-05 2021-04-05
PCT/US2021/031394 WO2021242505A1 (en) 2020-05-08 2021-05-07 Inhibitors of nek7 kinase

Publications (1)

Publication Number Publication Date
MX2022013984A true MX2022013984A (es) 2023-01-30

Family

ID=77774963

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013984A MX2022013984A (es) 2020-05-08 2021-05-07 Inhibidores de cinasa 7 relacionada con el gen nunca en mitosis a (nek7).

Country Status (13)

Country Link
US (3) US11161852B1 (es)
EP (1) EP4146348A1 (es)
JP (1) JP2023524597A (es)
KR (1) KR20230008763A (es)
CN (1) CN115843272A (es)
AU (1) AU2021280893A1 (es)
BR (1) BR112022022669A2 (es)
CA (1) CA3182276A1 (es)
CO (1) CO2022017622A2 (es)
IL (1) IL297979A (es)
MX (1) MX2022013984A (es)
TW (1) TW202208356A (es)
WO (1) WO2021242505A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022013984A (es) * 2020-05-08 2023-01-30 Halia Therapeutics Inc Inhibidores de cinasa 7 relacionada con el gen nunca en mitosis a (nek7).
CN114751874A (zh) * 2022-05-30 2022-07-15 江南大学 作为TRPV4-KCa2.3促耦联剂的1-苄基-4-乙基哌嗪衍生物及其应用
JP2024032686A (ja) * 2022-08-29 2024-03-12 日本たばこ産業株式会社 ピラゾロピリミジン化合物及びその医薬用途
US20240158394A1 (en) * 2022-09-14 2024-05-16 Halia Therapeutics, Inc. Nek7 inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
CA2737639A1 (en) 2008-09-25 2010-04-01 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the cb2 receptor
EP2467137A1 (en) 2009-08-19 2012-06-27 Ambit Biosciences Corporation Biaryl compounds and methods of use thereof
JP2013525308A (ja) 2010-04-16 2013-06-20 キュリス，インコーポレイテッド Ｋ−ｒａｓ変異を有する癌の治療
JP2015504889A (ja) 2012-01-12 2015-02-16 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 除草性イソオキサゾロ［５，４−ｂ］ピリジン
CN105431436B (zh) 2013-05-14 2017-11-28 内尔维阿诺医学科学有限公司 吡咯并[2,3‑d]嘧啶衍生物，它们的制备方法和它们作为激酶抑制剂的用途
MX2017006366A (es) 2014-11-14 2018-02-01 Nerviano Medical Sciences Srl Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteina quinasa.
SI3359541T1 (sl) 2015-10-09 2021-01-29 Abbvie Overseas S.A R.L. N-sulfonirani pirazolo(3,4 b)piridin-6-karboksamidi in postopki uporabe
US10167703B2 (en) 2016-03-31 2019-01-01 Saudi Arabian Oil Company Optimal well placement under constraints
KR102500416B1 (ko) 2016-06-21 2023-02-17 네르비아노 메디칼 사이언시스 에스.알.엘. 키나제 억제제로서의 n-(치환된-페닐)-설폰아미드 유도체
EP3487503A1 (en) 2016-07-20 2019-05-29 GlaxoSmithKline Intellectual Property Development Limited Isoquinoline derivatives as perk inhibitors
CN111315733A (zh) 2017-11-09 2020-06-19 英夫拉索姆有限公司 新颖磺酰胺甲酰胺化合物
WO2019192962A1 (en) * 2018-04-05 2019-10-10 Merck Patent Gmbh Heteroaryl compounds as type ii irak inhibitors and uses hereof
CN111646995B (zh) * 2019-03-04 2023-03-21 四川大学 4-氨基-嘧啶并氮杂环-苯基脲类衍生物及其制备方法和用途
AU2020355359B2 (en) * 2019-09-26 2023-08-24 Shenzhen Targetrx, Inc. Substituted aromatic fused ring derivative and composition comprising same, and use thereof
WO2021184154A1 (en) 2020-03-16 2021-09-23 Flash Therapeutics, Llc Compounds for treating or inhibiting recurrence of acute myeloid leukemia
MX2022013984A (es) * 2020-05-08 2023-01-30 Halia Therapeutics Inc Inhibidores de cinasa 7 relacionada con el gen nunca en mitosis a (nek7).

Also Published As

Publication number Publication date
CO2022017622A2 (es) 2022-12-20
EP4146348A1 (en) 2023-03-15
AU2021280893A1 (en) 2023-01-05
IL297979A (en) 2023-01-01
CN115843272A (zh) 2023-03-24
KR20230008763A (ko) 2023-01-16
CA3182276A1 (en) 2021-12-02
US20230416259A1 (en) 2023-12-28
US11713321B2 (en) 2023-08-01
TW202208356A (zh) 2022-03-01
US20210355130A1 (en) 2021-11-18
US20220064173A1 (en) 2022-03-03
WO2021242505A1 (en) 2021-12-02
BR112022022669A2 (pt) 2023-01-17
US11161852B1 (en) 2021-11-02
JP2023524597A (ja) 2023-06-12

Similar Documents

Publication Publication Date Title
MX2022013984A (es) Inhibidores de cinasa 7 relacionada con el gen nunca en mitosis a (nek7).
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
MX2019013954A (es) Inhibidores covalentes de kras.
MX2022007350A (es) Derivados de pirazolilo utiles como agentes anticancerigenos.
MX2020013817A (es) Compuestos de naftiridinona sustituidos utiles como activadores de celulas t.
CA3057882A1 (en) Substituted dihydro-spiro-napthalene-oxa derivatives and pharmaceutical compositions thereof useful as inhibitors of mcl-1 protein
MX2020013373A (es) Compuestos de naftiridinona utiles como activadores de celulas t.
WO2016164675A8 (en) Substituted quinazoline compounds and methods of use thereof
MX2023007192A (es) Inhibidores de prmt5.
WO2021055728A8 (en) Small molecule inhibitors of kras g12c mutant
MX2009013832A (es) Derivados de purina y su uso como moduladores del receptor 7 similar a un puente.
MX2022015495A (es) Inhibidores de cinasa relacionada con el gen a nunca en mitosis (nek7).
MX2022007130A (es) Derivados de piperazina sustituidos utiles como activadores de celulas t.
MX2021010106A (es) Inhibidores de la via de respuesta al estres integrada.
MX2021015543A (es) Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo.
AU2019375825A8 (en) Macrocyclic tyrosine kinase inhibitor and uses thereof
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
MX2022001789A (es) Derivados de 2-hidroxicicloalcan-1-carbamoilo.
CR20220538A (es) Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso
CO2023014204A2 (es) Inhibidores de la cinasa relacionada con el gen nunca en mitosis a 7 (nek7)
MX2022004213A (es) Derivados de 2-azaspiro[3.4]octano como agonistas de m4.
MX2023011027A (es) Derivados de pirimidina utiles como inhibidores de la proteina cinasa de repeticion 2 rica en leucina (lrrk2).
MX2022004215A (es) Derivados de 2-azaespiro[3.4]octano como agonistas de m4.
MX2022006104A (es) Composicion farmaceutica oral que comprende compuesto de carbamato y metodo de preparacion para la misma.
MX2022003617A (es) Derivados heterociclicos, composiciones farmaceuticas y su uso en el tratamiento o mejora del cancer.